Re: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer

被引：0

作者：

Malayeri, R ^{[1
]}

机构：

[1] Royal Free Hosp, Sch Med, Dept Acad Haematol, London NW3 2PF, England

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2002年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1172 / 1172

页数：1

共 6 条

[1] Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial [J].

Kelly, K ;

Crowley, J ;

Bunn, PA ;

Presant, CA ;

Grevstad, PK ;

Mainpour, CM ;

Ramsey, SD ;

Wozniak, AJ ;

Weiss, GR ;

Moore, DF ;

Israel, VK ;

Livingston, RB ;

Gandara, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3210-3218

[2] New drugs in the palliative chemotherapy of advanced non-small-cell lung cancer [J].

Malayeri, R ;

Pirker, R ;

Huber, H .

ONKOLOGIE, 2001, 24 (05) :416-421

[3] Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer [J].

Ramsey, SD ;

Moinpour, CM ;

Lovato, LC ;

Crowley, JJ ;

Grevstad, P ;

Presant, CA ;

Rivkin, SE ;

Kelly, K ;

Gandara, DR .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (04) :291-297

[4] Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? [J].

Soria, JC ;

Brisgand, D ;

Le Chevalier, T .

ANNALS OF ONCOLOGY, 2001, 12 (12) :1667-1670

[5]

Sweeney CJ, 2001, CANCER, V92, P2639, DOI 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO

[6]

2-8

← 1 →